Enrolling by invitationPHASE1, PHASE2NCT06851767
Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy
Studying T-B+ severe combined immunodeficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Suk S De Ravin, M.D.National Institute of Allergy and Infectious Diseases (NIAID)
- Intervention
- Plerixafor(genetic)
- Enrollment
- 18 enrolled
- Eligibility
- 3-99 years · MALE
- Timeline
- 2025 – 2034
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06851767 on ClinicalTrials.govOther trials for T-B+ severe combined immunodeficiency
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT03619551Conditioning SCID Infants Diagnosed EarlyCenter for International Blood and Marrow Transplant Research
- RECRUITINGPHASE1, PHASE2NCT01306019Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)National Institute of Allergy and Infectious Diseases (NIAID)